Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Lu, Wenxia ^a,b   Li, Sainan ^a   Li, Jingjing ^a   Wang, Jianrong ^a,b   Zhang, Rong ^a,b   Zhou, Yuqing ^a,c   Yin, Qin ^a,c   Zheng, Yuanyuan ^a   Wang, Fan ^a   Xia, Yujing ^a   Chen, Kan ^a   Liu, Tong ^a   Lu, Jie ^a   Zhou, Yingqun ^a   Guo, Chuanyong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINESE BIOMEDICAL DATABASE; CHOLESTEROL BLOOD LEVEL; CINAHL; CNKI DATABASE; COCHRANE LIBRARY; EMBASE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MEDLINE; META ANALYSIS; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCISEARCH; SUPPLEMENTATION; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84987922596     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/1459790     Document Type: Article

References (47)

1. P. Angulo, "Nonalcoholic fatty liver disease," The New England Journal of Medicine, vol. 346, no. 16, pp. 1221-1231, 2002.
2. F.-S. Zhu, S. Liu, X.-M. Chen, Z.-G. Huang, and D.-W. Zhang, "Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia," World Journal of Gastroenterology, vol. 14, no. 41, pp. 6395-6400, 2008.
3. M. R. Pagadala and A. J. McCullough, "The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis," Clinics in Liver Disease, vol. 16, no. 3, pp. 487-504, 2012.
4. J. Lizardi-Cervera and D. Aguilar-Zapata, "Nonalcoholic fatty liver disease and its association with cardiovascular disease," Annals of Hepatology, vol. 8, no. 1, pp. S40-S43, 2009.
5. G. Targher, C. P. Day, and E. Bonora, "Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease," The New England Journal of Medicine, vol. 363, no. 14, pp. 1341-1350, 2010.
6. L. S. Bhatia, N. P. Curzen, P. C. Calder, and C. D. Byrne, "Nonalcoholic fatty liver disease: a new and important cardiovascular risk factor?" European Heart Journal, vol. 33, no. 10, pp. 1190-1200, 2012.
7. G. Targher and C. D. Byrne, "Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications," Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 2, pp. 483-495, 2013.
8. C. K. Argo, P. G. Northup, A. M. S. Al-Osaimi, and S. H. Caldwell, "Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis," Journal of Hepatology, vol. 51, no. 2, pp. 371-379, 2009.
9. N. Chalasani, Z. Younossi, J. E. Lavine et al., "The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology," Gastroenterology, vol. 142, no. 7, pp. 1592-1609, 2012.
10. A. P. Levene and R.D. Goldin, "The epidemiology, pathogenesis and histopathology of fatty liver disease," Histopathology, vol. 61, no. 2, pp. 141-152, 2012.
11. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease," Journal of Hepatology, vol. 64, no. 6, pp. 1388-1402, 2016.
12. M. Tiikkainen, A.-M. Häkkinen, E. Korsheninnikova, T. Nyman, S. Mäkimattila, and H. Yki-Järvinen, "Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes," Diabetes, vol. 53, no. 8, pp. 2169-2176, 2004.
13. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis," The New England Journal of Medicine, vol. 362, no. 18, pp. 1675-1685, 2010.
14. J. H. Hoofnagle, M. L. Van Natta, D. E. Kleiner et al., "Vitamin e and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis," Alimentary Pharmacology and Therapeutics, vol. 38, no. 2, pp. 134-143, 2013.
15. Z. M. Younossi, M. J. Reyes, A. Mishra, R. Mehta, and L. Henry, "Systematic review with meta-analysis: non-alcoholic steatohepatitis-a case for personalised treatment based on pathogenic targets," Alimentary Pharmacology and Therapeutics, vol. 39, no. 1, pp. 3-14, 2014.
16. N. Mazzella, L. M. Ricciardi, A. Mazzotti, and G. Marchesini, "The role of medications for the management of patients with NAFLD," Clinics in Liver Disease, vol. 18, no. 1, pp. 73-89, 2014.
17. V. Ratziu, Z. Goodman, and A. Sanyal, "Current efforts and trends in the treatment of NASH," Journal of Hepatology, vol. 62, no. 1, pp. S65-S75, 2015.
18. J. Araya, R. Rodrigo, L. A. Videla et al., "Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease," Clinical Science, vol. 106, no. 6, pp. 635-643, 2004.
19. K. Promrat, D. E. Kleiner, H. M. Niemeier et al., "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis," Hepatology, vol. 51, no. 1, pp. 121-129, 2010.
20. M. Lazo and J. M. Clark, "The epidemiology of nonalcoholic fatty liver disease: a global perspective," Seminars in Liver Disease, vol. 28, no. 4, pp. 339-350, 2008.
21. A. P. Simopoulos, "Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet," World Review of Nutrition and Dietetics, vol. 102, pp. 10-21, 2011.
22. I. P. J. Alwayn, K. Gura, V. Nosé et al., "Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease," Pediatric Research, vol. 57, no. 3, pp. 445-452, 2005.
23. M.-T. Wu, H.-N. Chou, and C.-J. Huang, "Dietary fucoxanthin increases metabolic rate and upregulated mRNA expressions of the PGC-1alpha network, mitochondrial biogenesis and fusion genes in white adipose tissues of mice," Marine Drugs, vol. 12, no. 2, pp. 964-982, 2014.
24. D. Kromhout, S. Yasuda, J. M. Geleijnse, and H. Shimokawa, "Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?" European Heart Journal, vol. 33, no. 4, pp. 436-443, 2012.
25. H. Zhang, J. Yang, R. Zhu et al., "Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis," Drug Design, Development and Therapy, vol. 9, pp. 567-574, 2015.
26. Y. Zhang, S. Li, L. He et al., "Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis," Drug Design, Development and Therapy, vol. 9, pp. 2757-2766, 2015.
27. C. K. Argo, J. T. Patrie, C. Lackner et al., "Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial," Journal of Hepatology, vol. 62, no. 1, pp. 190-197, 2015.
28. E. Scorletti, L. Bhatia, K. G. Mccormick et al., "Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME∗ study," Hepatology, vol. 60, no. 4, pp. 1211-1221, 2014.
29. A. J. Sanyal, M. F. Abdelmalek, A. Suzuki, O.W. Cummings, and M. Chojkier, "No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial," Gastroenterology, vol. 147, no. 2, pp. 377-384.e1, 2014.
30. F. Sofi, I. Giangrandi, F. Cesari et al., "Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study," International Journal of Food Sciences and Nutrition, vol. 61, no. 8, pp. 792-802, 2010.
31. S. Dasarathy, J. Dasarathy, A. Khiyami et al., "Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis," Journal of Clinical Gastroenterology, vol. 49, no. 2, pp. 137-144, 2015.
32. L. Spadaro, O. Magliocco, D. Spampinato et al., "Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease," Digestive and Liver Disease, vol. 40, no. 3, pp. 194-199, 2008.
33. M. Capanni, F. Calella, M. R. Biagini et al., "Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study," Alimentary Pharmacology and Therapeutics, vol. 23, no. 8, pp. 1143-1151, 2006.
34. G. L. Vega, M. Chandalia, L. S. Szczepaniak, and S. M. Grundy, "Effects of N-3 fatty acids on hepatic triglyceride content in humans," Journal of Investigative Medicine, vol. 56, no. 5, pp. 780-785, 2008.
35. R. Chen, Q. Guo, W.-J. Zhu, Q. Xie, H. Wang, and W. Cai, "Therapeutic efficacy of ω-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease," World Chinese Journal of Digestology, vol. 16, no. 18, pp. 2002-2006, 2008.
36. I.P. J. Alwayn, C. Andersson, B. Zauscher, K. Gura, V. Nosé, and M. Puder, "Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor," Transplantation, vol. 79, no. 5, pp. 606-608, 2005.
37. H. M. Parker, N. A. Johnson, C. A. Burdon, J. S. Cohn, H. T. O'Connor, and J. George, "Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and metaanalysis," Journal of Hepatology, vol. 56, no. 4, pp. 944-951, 2012.
38. N. Tanaka, K. Sano, A. Horiuchi, E. Tanaka, K. Kiyosawa, and T. Aoyama, "Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis," Journal of Clinical Gastroenterology, vol. 42, no. 4, pp. 413-418, 2008.
39. J. Zúñiga, M. Cancino, F. Medina et al., "N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemiareperfusion injury," PLoS ONE, vol. 6, no. 12, Article IDe28502, 2011.
40. Y. B. Lombardo and A. G. Chicco, "Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review," Journal of Nutritional Biochemistry, vol. 17, no. 1, pp. 1-13, 2006.
41. H. Ishii, Y. Horie, S. Ohshima et al., "Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice," Journal of Hepatology, vol. 50, no. 3, pp. 562-571, 2009.
42. H. Cortez-Pinto, L. Jesus, H. Barros, C. Lopes, M. C. Moura, and M. E. Camilo, "How different is the dietary pattern in nonalcoholic steatohepatitis patients?" Clinical Nutrition, vol. 25, no. 5, pp. 816-823, 2006.
43. K. Toshimitsu, B. Matsuura, I. Ohkubo et al., "Dietary habits and nutrient intake in non-alcoholic steatohepatitis," Nutrition, vol. 23, no. 1, pp. 46-52, 2007.
44. A. M. Zivkovic, J. B. German, and A. J. Sanyal, "Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease," American Journal of Clinical Nutrition, vol. 86, no. 2, pp. 285-300, 2007.
45. P. Cheng, K. Chen, Y. Xia et al., "Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis," Drug Design, Development and Therapy, vol. 8, pp. 1277-1286, 2014.
46. W. Dai, F. Wang, L. He et al., "Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial mesenchymal transition: partial mediation by the transcription factor NFAT1," Molecular Carcinogenesis, vol. 54, no. 4, pp. 301-311, 2015.
47. W. Dai, F. Wang, J. Lu et al., "By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice," Oncotarget, vol. 6, no. 15, pp. 13703-13717, 2015.